These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 20024612)

  • 21. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
    Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
    Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y; Li X; Jiang J; Frank SJ
    Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene.
    Liu J; Spence MJ; Wallace PM; Forcier K; Hellström I; Vestal RE
    Cell Growth Differ; 1997 Jun; 8(6):667-76. PubMed ID: 9186000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins.
    Koziczak M; Holbro T; Hynes NE
    Oncogene; 2004 Apr; 23(20):3501-8. PubMed ID: 15116089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats.
    Lin HC; Huang YT; Yang YY; Lee PC; Hwang LH; Lee WP; Kuo YJ; Lee KC; Hsieh YC; Liu RS
    J Gastroenterol Hepatol; 2014 May; 29(5):1073-82. PubMed ID: 24325631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated NRD1 metalloprotease expression plays a role in breast cancer growth and proliferation.
    Choong LY; Lim SK; Chen Y; Loh MC; Toy W; Wong CY; Salto-Tellez M; Shah N; Lim YP
    Genes Chromosomes Cancer; 2011 Oct; 50(10):837-47. PubMed ID: 21769958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells.
    Moffa AB; Tannheimer SL; Ethier SP
    Mol Cancer Res; 2004 Nov; 2(11):643-52. PubMed ID: 15561780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brivanib alaninate for cancer.
    Diaz-Padilla I; Siu LL
    Expert Opin Investig Drugs; 2011 Apr; 20(4):577-86. PubMed ID: 21391890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE.
    Tannheimer SL; Rehemtulla A; Ethier SP
    Breast Cancer Res; 2000; 2(4):311-20. PubMed ID: 11056689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.
    Patel RR; Sengupta S; Kim HR; Klein-Szanto AJ; Pyle JR; Zhu F; Li T; Ross EA; Oseni S; Fargnoli J; Jordan VC
    Eur J Cancer; 2010 Jun; 46(9):1537-53. PubMed ID: 20303261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NCAM-mimetic, FGL peptide, restores disrupted fibroblast growth factor receptor (FGFR) phosphorylation and FGFR mediated signaling in neural cell adhesion molecule (NCAM)-deficient mice.
    Aonurm-Helm A; Berezin V; Bock E; Zharkovsky A
    Brain Res; 2010 Jan; 1309():1-8. PubMed ID: 19909731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
    Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
    Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
    Brown WS; Akhand SS; Wendt MK
    Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibroblast growth factor-2 up-regulates the expression of nestin through the Ras-Raf-ERK-Sp1 signaling axis in C6 glioma cells.
    Chang KW; Huang YL; Wong ZR; Su PH; Huang BM; Ju TK; Yang HY
    Biochem Biophys Res Commun; 2013 May; 434(4):854-60. PubMed ID: 23611784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
    Turner N; Pearson A; Sharpe R; Lambros M; Geyer F; Lopez-Garcia MA; Natrajan R; Marchio C; Iorns E; Mackay A; Gillett C; Grigoriadis A; Tutt A; Reis-Filho JS; Ashworth A
    Cancer Res; 2010 Mar; 70(5):2085-94. PubMed ID: 20179196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer.
    Zammit C; Barnard R; Gomm J; Coope R; Shousha S; Coombes C; Johnston C
    J Pathol; 2001 May; 194(1):27-34. PubMed ID: 11329138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.
    Bhide RS; Lombardo LJ; Hunt JT; Cai ZW; Barrish JC; Galbraith S; Jeyaseelan R; Mortillo S; Wautlet BS; Krishnan B; Kukral D; Malone H; Lewin AC; Henley BJ; Fargnoli J
    Mol Cancer Ther; 2010 Feb; 9(2):369-78. PubMed ID: 20103604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
    Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
    Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.